Jenilee Cueto

Jenilee Cueto

Auto-generated profile, based on publicly available information

Jenilee Cueto

Daiichi-Sankyo, Inc., Basking Ridge, NJ 07920, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Breast
Verified
Journal Article
Open access
ESElizabeth M. Salvo
Elizabeth M. Salvo
ARAbril Oliva Ramirez
Abril Oliva Ramirez
JCJenilee Cueto
Jenilee Cueto
ELErnest H. Law
Ernest H. Law
ASAaron Situ
Aaron Situ
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. Randomized controlled trials (RCTs) and real-world evidence (RWE) studies were identified using Ovid MEDLINE®, Embase, and Evidence-Based Medicine Reviews. Clinical and methodological similarities including alignment of outcome definitions with standardized definitions for efficacy endpoints criteria were assessed to evaluate feasibility of conducting a meta-analysis. Where feasible, 5-year probabilities of BC recurrence or death were estimated using a Bayesian hierarchical arm-based model. Of 21 included studies, 8 RCTs and 4 RWE studies reported outcome data of interest. There was heterogeneity in outcome reporting, as well as variation in recurrence risk amongst studies with aligned reporting. Of the 12 studies, 10 were considered for inclusion in a meta-analysis of BC recurrence or death. Only a subgroup analysis of node-positive patients (3 studies; n = 7307) was deemed feasible. The 5-year probability of BC recurrence or death was 17.2% (95% credible interval: 14.6%-20.3%). Although studies reporting recurrence outcomes were limited, there remains a high risk of BC recurrence, especially among node-positive patients. Approximately 1 in 6 women with node-positive HR+/HER2- early-stage BC receiving endocrine therapy experience recurrence or death within 5-years of initiating treatment, suggesting a need for novel treatments for this population.

15 March 2024 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
MHMackenzie Henderson
Mackenzie Henderson
PYPriyanka Yalamanchili
Priyanka Yalamanchili
JCJenilee Cueto
Jenilee Cueto
ZIZahidul Islam
Zahidul Islam
MSMaribel Salas
Maribel Salas
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...

22 June 2023 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
NTNora Tu
Nora Tu
OFOluwatosin Fofah
Oluwatosin Fofah
JCJenilee Cueto
Jenilee Cueto
YKYasser Mostafa Kamel
Yasser Mostafa Kamel
Aim: Elderly acute myeloid leukemia (AML) patients are often not treated with antileukemic therapy due to their poor overall health condition, leaving supportive care as the sole treatment option. ... Plain language summary - Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment p...